Newsletter Signup x
Osteosarcoma (OS) is a type of bone tumour that mostly affects children and young adults. Survival rates have improved little over the past four decades and better treatments are desperately needed. There is evidence to suggest that inhibiting a protein, called ZFP36L1, in OS cells could make existing drugs more effective. In this pilot study, Dr John Murphy and his team will seek to verify this by removing the gene for ZFP36L1 in OS cells in a “test-tube” setting. The results could pave the way for the development of anti- ZFP36L1 drugs for OS.
A pilot Investigation of the ZFP36L1 protein as a candidate therapeutic target in osteosarcoma cells
Dr John Murphy
University of Westminster
London, W1W 6UW
1 January 2021
18 months
£14,013
Patient Story – Finley
Finley was diagnosed with acute lymphoblastic leukaemia in September 2020 when he was four years old. His dad Martin
Read more